DNTH

Dianthus Therapeutics is a biotech company developing medicines for severe autoimmune diseases, where the body's immune system attacks itself. The company's main experimental drug, claseprubart, is designed to block a specific protein involved in immune system activation. Another experimental treatment targets immune cells that produce damaging inflammation while also blocking signals that activate B cells, which are another part of the immune system involved in autoimmune disease. The company was founded in 2019 and is based in New York.